3,730 reports of this reaction
4.3% of all RIBOCICLIB reports
#1 most reported adverse reaction
NEUTROPENIA is the #1 most commonly reported adverse reaction for RIBOCICLIB, manufactured by Novartis Pharmaceuticals Corporation. There are 3,730 FDA adverse event reports linking RIBOCICLIB to NEUTROPENIA. This represents approximately 4.3% of all 86,238 adverse event reports for this drug.
RIBOCICLIB has an overall safety score of 85 out of 100. Patients taking RIBOCICLIB who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among RIBOCICLIB users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for RIBOCICLIB:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 3,730 FDA reports for RIBOCICLIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 4.3% of all adverse event reports for RIBOCICLIB, making it one of the most commonly reported side effect.
If you experience neutropenia while taking RIBOCICLIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.